BioStock: Mentice comments on strong Q4 financial performance

Mentice ended the year on a high note with a strong Q4, driven by large orders from top medical device companies. However, full-year order intake declined, and some challenges remain to achieve strong, sustained growth. Newly appointed CEO Frans Venker emphasized the need to enhance commercial execution in the US market and leverage new products to drive accelerated growth.

Read the full article at biostock.se:

https://www.biostock.se/en/2025/02/mentice-comments-on-strong-q4-financial-performance/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se